Adding Dostarlimab Improves Progression-Free Survival in Endometrial Cancer
Dostarlimab plus carboplatin-paclitaxel linked to increased progression-free survival overall and in dMMR-MSI-H population
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.